Clinical trials: Reduced Ejection Fraction Heart Failure
Heart Failure With Reduced Ejection Fraction
Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure
This study evaluate the dosage of bisoprolol plasma residual concentrations in chronic heart failure with mild to reduced ejection fraction adult patients by dose and renal function.
- Trial name
- PREVALENT (NCT03644446)
- Testing
- Bisoprolol plasma residual concentration dosage
- Where
- France
- Volunteers
- 81 people
- Sponsor
- University Hospital, Caen
Heart Failure With Reduced Ejection Fraction
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
- Trial name
- VANGUARD (NCT02113033)
- Testing
- Equilia® Vagal Nerve Stimulation
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 15 people
- Sponsor
- LivaNova
Heart Failure With Reduced Ejection Fraction, Vitamin D Deficiency
Supplementation With Vitamin D to Patients With Heart Failure (D-Heart).
In 200 patients with documented systolic heart failure give supplementation with vitamin D in those with a 25-OH- vitamin D < 50nmol/L - or placebo.
- Trial name
- D-Heart (NCT03289637)
- Testing
- Vitamin D
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Linkoeping University
Heart Failure With Reduced Ejection Fraction
Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment
The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronization therapy and/or an…
- Trial name
- CHILISALT (NCT03359967)
- Testing
- Entresto tablet
- Volunteers
- 24 people
- Sponsor
- Central Hospital, Izmir
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Hyperemic Efficacy of IV Adenosine in HFrEF
Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies.
- Trial name
- HF-FFR (NCT03235700)
- Testing
- Maximal hyperemia with adenosine followed by nicorandil, Maximal hyperemia with nicorandil followed by adenosine
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Sejong General Hospital
Heart Failure With Reduced Ejection Fraction, Renal Insufficiency
Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency
Effect of high calorie high protein diet versus high calorie,glomerular filtration rate (GFR) based protein intake in non-obese advanced HF patients will be assessed.
- Trial name
- GFR (NCT03213821)
- Testing
- protein intake
- Volunteers
- 100 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Heart Failure With Reduced Ejection Fraction
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Assessment of clinical effect and treatment quality of immediate release carvedilol (IR) versus slow release carvedilol (SR) in patients with HFrEF
- Trial name
- SLOW-HF (NCT03209180)
- Testing
- CarVeDilol-SR (Slow Release), Carvedilol IR (Immediate Release)
- Where
- 13 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Seoul National University Bundang Hospital
Heart Failure, Dilated Cardiomyopathy
A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
AUGMENT-HF II is a study to evaluate the efficacy and safety of the Algisyl device. The purpose of this study is to investigate Algisyl employed as a method of left ventricular augmentation and restoration in patients with…
- Conditions
- Heart Failure, Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction
- Trial name
- AUGMENT-HFII (NCT03082508)
- Testing
- Algisyl, Standard Medical Therapy
- Volunteers
- 240 people
- Sponsor
- LoneStar Heart, Inc.
Defibrillators, Implantable, Heart Failure With Reduced Ejection Fraction
Multi-centre Observational Registry on Patients With Implantable Devices Remotely Monitored
Multicentric, observational, retrospective registry including patients underwent implantable device implantation (pacemaker or ICD) for any indication in the period from 2009 to 2016, followed by remote monitoring.
- Conditions
- Defibrillators, Implantable, Heart Failure With Reduced Ejection Fraction, Arrythmia, Pacemaker
- Trial name
- IMPLANTED (NCT03061747)
- Testing
- Assesment of outcome of implantable device patients
- Where
- 6 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda Ospedaliera Cardinale G. Panico
Patients With Heart Failure and Preserved Ejection Fraction - HFpEF, Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction (DIAMONDHFpEF)
The investigators wish to test a hypothesis that patients with HFpEF have different characteristics on echo, cardiac MRI and plasma protein \& chemical profiles compared to HFrEF and healthy volunteers.
- Conditions
- Patients With Heart Failure and Preserved Ejection Fraction - HFpEF, Patients With Heart Failure With Reduced Ejection Fraction - HFrEF, Healthy Controls Group - Age and Sex-matched
- Trial name
- DIAMONDHFpEF (NCT03050593)
- Testing
- MRI scan, Echo scan
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed…
- Trial name
- TITRATION (NCT01922089)
- Testing
- LCZ696
- Where
- 105 sites in United States, Bulgaria and 9 more
- Volunteers
- 498 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers
Cardiac resynchronization therapy (CRT) is one of the lastest recommended treatments in patients with refractory symptomatic chronic heart failure with reduced ejection fraction (HFREF).
- Trial name
- PREFAC-CRT (NCT02018029)
- Testing
- cardiac resynchronisation therapy
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Failure, Reduced Left Ventricular Ejection Fraction
EP-Catheter Guided CS-Lead Implantation
In patients undergoing CRT device implantation a lead positioning in the coronary sinus is required. Even this part of the surgical procedure is challenging.
- Conditions
- Heart Failure, Reduced Left Ventricular Ejection Fraction, Left Bundle Branch Block
- Trial name
- NCT01922544
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University of Cologne